Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours

British Journal of Cancer

Volumn 74, Issue 11, 1996, Pages 1730-1733

  Sargent, J M ^a   Elgie, A W ^a   Williamson, C J ^a   Taylor, C G ^a  

^a Pembury Hospital   (United Kingdom)

Author keywords

Aphidicolin; Cisplatin; DNA repair; Primary tumours; Resistance modulation

Indexed keywords

APHIDICOLIN; CARBOPLATIN; CISPLATIN; DNA POLYMERASE;

ARTICLE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG EFFECT; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LC 50; OVARY CANCER; PRIORITY JOURNAL;

EID: 0029851151     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.622     Document Type: Article

References (26)

1. BEKETIC-ORESKOVIC L AND OSMAK M. (1995). Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells. Cancer Chemother. Pharmacol., 35, 327-333.
2. BOULTON S, PEMBERTON LC, PORTEOUS JK, CURTIN NJ, GRIFFIN RJ, GOLDING BT AND DURKACZ BW. (1995). Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br. J. Cancer, 72, 849-856.
3. CHAO CC-K. (1994). Enhanced excision repair of DNA damage due to cis-diamminedichloroplatinum(II) in resistant cervix carcinoma HeLa cells. Eur. J. Pharmacol., 268, 347-355.
4. DAMIA G, TAGLIABUE G, ZUCCHETTI M, DAVOLI E, SESSA C, CAVALLI F AND D'INCALCI M. (1992). Activity of aphidicolin glycinate alone and in combination with cisplatin in a murine ovarian tumour resistant to cisplatin. Cancer Chemother. Pharmacol., 30, 459-464.
5. DEMPKE WCM, SHELLARD SA, FICHTINGER-SCHEPMAN AMJ AND HILL BT. (1991). Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro. Carcinogenesis, 12, 525-528.
6. EASTMAN A. (1990). Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells, 2, 275-280.
7. EASTMAN A AND SCHULTE N. (1988). Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry, 27, 4730-4734.
8. FRIEDLANDER ML. (1992). Drug resistance in ovarian cancer. Int. J. Gynecol. Cancer, (suppl. 1), 2-9.
9. GORMLEY PE, BULL JM, LEROY AF AND CYSYK R. (1979). Kinetics of cis-dichlorodiammineplatinum. Clin. Pharmacol. Ther., 23, 351-357.
10. HENGSTLER JG, FUCHS J AND OESCH F. (1992). DNA strand breaks and DNA cross-links in peripheral mononuclear cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res., 52, 5622-5626.
11. HILLS CA, KELLAND LR, ABEL G, SIRACKY J, WILSON AP AND HARRAP KR. (1989). Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer, 59, 527-534.
12. KAYE SB. (1993). Chemotherapy for ovarian cancer. Eur. J. Cancer, 29, 632-635.
13. KAYE SB, LEWIS CR, PAUL J, DUNCAN D, GORDON HK, KITCHENER HC, CRUICKSHANK DJ, ATKINSON RJ, SOUKOP M, RANKIN EM, CASSIDY J, DAVIS JA, REED NS, CRAWFORD SM, MacLEAN A, SWAPP GA, SARKER TK, KENNEDY JH AND SYMONDS RP. (1992). Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet, 340, 329-333.
14. MASUDA H, OZOLS RF, LAI G-M, FOJO A, ROTHENBERG M AND HAMILTON T. (1988). Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res., 48, 5713-5716.
15. MORGAN RJ, MARGOLIN K, RASCHKO J, AKMAN S, LEONG L, SOMLO G, SCANLON K, AHN C, CARROLL M AND DOROSHOW JH. (1995). Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy. J. Clin. Oncol., 13, 2238-2246.
16. NEWELL DR, SIDDICK ZH, GUMBRELL LA, BOXALL FE, GORE ME, SMITH IE AND CALVERT AH. (1987). Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur. J. Cancer Clin. Oncol., 23, 1399-1405.
17. O'DWYER PJ, MOYER JD, SUFFNESS M, HARRISON SD, CYSYK R, HAMILTON TC AND PLOWMAN J. (1994). Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res., 54, 724-729.
18. O'DWYER PJ, HAMILTON TC, LACRETA FP, GALLO JM, KILPATRICK D, HALBHERR T, BRENNAN J, BOOKMAN M, HOFFMAN J, YOUNG RC, COMIS RL AND OZOLS RF. (1996). Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J. Clin. Oncol., 14, 249-256.
19. OZOLS RF. (1992). Chemotherapy for advanced epithelial ovarian cancer. Haematol. Oncol. Clin. N. Am., 6, 879-894.
20. PARKINSON EK. (1996). Do telomerase antagonists represent a novel anti-cancer strategy? Br. J. Cancer, 73, 1-4.
21. PEREZ RP, HAMILTON TC, OZOLS RF AND YOUNG RC. (1993). Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer (suppl.), 71, 1571-1580.
22. REED E, OZOLS R, TARONE R, YUSPA SH AND POIRIER MC. (1987). Platinum DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl Acatl. Sci. USA, 84, 5024-5028.
23. SARGENT J, ELGIE A, TAYLOR CG, WILSON J, ALTON P AND HILL JG. (1994a). The identification of drug resistance in ovarian cancer and breast cancer: application of the MTT assay. In Chemosensitivity Testing in Gynecologic Malignancies and Breast Cancer. Contrib. Gynecol. Obstet, vol 19, Kochli OR, Sevin B-U and Haller U. (eds) pp. 64-75, Karger: Basle.
24. SARGENT J, TAYLOR C, ELGIE A AND WILLIAMSON C. (1994b). In vitro modification of drug resistance in fresh tumor cells from patients with ovarian cancer. Anti-Cancer Drugs, 5 (suppl. 1), 61.
25. SESSA C, ZUCCHETTI M, DAVOLI E, CALIFANO R, CAVALLI F, FRUSTACI S, GUMBRELL L, SULKES A, WINOGRAD B AND D'INCALCI M. (1991). Phase I and clinical evaluation of aphidicolin glycinate. J. Natl Cancer Inst., 83, 1160-1164.
26. WILSON JK, SARGENT JM, ELGIE AW, HILL JG AND TAYLOR CG. (1990). A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br. J. Cancer, 62, 189-194.